Prentice Stovall, Jr. serves as the Global Development Leader for a molecule currently in phase 3 trials for multiple autoimmune diseases. In this role at Lilly, Prentice leads the molecule strategy, which includes team formation, lifecycle planning, key regulatory interactions, regulatory approval oversight, and scientific narrative development for internal and external parties. Prentice has held a wide range of roles during his 11 years at Lilly including marketing, market research, forecasting, sales, development, and leadership. He has spent time living outside of the U.S., leading the oncology business in Canada and serving on Lilly Canada’s leadership team. Previously, he served as the chair of the African American Network (AAN), one of the largest employee resource groups at Lilly. He played a leadership role in accelerating the diversity and inclusion efforts for the company and in the community. His time as the chair was defined by his ability to reimagine the AAN, set a clear strategy, and activate the membership. Prior to Lilly, Prentice received his Bachelors of Science from Purdue University in 2003 and his Masters of Business Administration from the Krannert School of Management in 2009.

Register Here: https://unc.az1.qualtrics.com/jfe/form/SV_50Z1g6gdLgLYwtv